BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Dasatinib is a second generation multitargeted tyrosine kinase inhibitor (TKI) directed against BCR-ABL, which is approved for the treatment of Philadelphia chromosome positive (Ph+) leukemias, including newly diagnosed chronic myeloid leukemia (CML) in the chronic phase (Talpaz et al., 2006; Jabbour and Lipton, 2013).